Long-term follow-up of the French Stop Imatinib (STIM1) study in patients with chronic myeloid leukemia

Journal of Clinical Oncology

Volumn 35, Issue 3, 2017, Pages 298-305

  Etienne, Gabriel ^a   Guilhot, Joëlle ^b   Rea, Delphine ^c   Rigal Huguet, Françoise ^e   Nicolini, Franck ^f   Charbonnier, Aude ^g   Guerci Bresler, Agnès ^h   Legros, Laurence ⁱ   Varet, Bruno ^d   Gardembas, Martine ^j   Dubruille, Viviane ^k   Tulliez, Michel ^l   Noel, Marie Pierre ^m   Ianotto, Jean Christophe ⁿ   Villemagne, Bruno ^o   Carré, Martin ^p   Guilhot, François ^b   Rousselot, Philippe ^q   Mahon, François Xavier ^a,r  

^a INSTITUT BERGONIÉ   (France)

^b POITIERS UNIVERSITY HOSPITAL   (France)

^c SAINT LOUIS HOSPITAL   (France)

^d HÔPITAL NECKER ENFANTS MALADES   (France)

^e Institut Universitaire du Cancer Toulouse Oncopole   (France)

^f CENTRE HOSPITALIER LYON SUD   (France)

^g INSTITUT PAOLI CALMETTES   (France)

^h CHU NANCY BRABOIS   (France)

ⁱ CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^j ANGERS UNIVERSITY HOSPITAL   (France)

^k HÔTEL DIEU   (France)

^l HENRI MONDOR HOSPITAL   (France)

^m LILLE UNIVERSITY HOSPITAL   (France)

ⁿ CHU MORVAN   (France)

^o Service de Reanimation Polyvalente   (France)

^p HÔPITAL MICHALLON   (France)

^q CENTRE HOSPITALIER DE VERSAILLES   (France)

^r BORDEAUX UNIVERSITY HOSPITAL   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; BOSUTINIB; DASATINIB; IMATINIB; NILOTINIB; ANTINEOPLASTIC AGENT; BCR-ABL1 FUSION PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER RECURRENCE; CHRONIC MYELOID LEUKEMIA; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK ASSESSMENT; SOKAL RISK SCORE; TREATMENT DURATION; TREATMENT RESPONSE; VERY ELDERLY; CLINICAL TRIAL; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; ENZYMOLOGY; FRANCE; GENETICS; KAPLAN MEIER METHOD; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MIDDLE AGED; MOLECULAR DIAGNOSIS; MULTICENTER STUDY; PATHOLOGY; PATIENT SELECTION; PREDICTIVE VALUE; PROSPECTIVE STUDY; RECURRENT DISEASE; RISK FACTOR; TIME FACTOR; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; FRANCE; FUSION PROTEINS, BCR-ABL; HUMANS; IMATINIB MESYLATE; KAPLAN-MEIER ESTIMATE; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; MOLECULAR DIAGNOSTIC TECHNIQUES; NEOPLASM, RESIDUAL; PATIENT SELECTION; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; PROTEIN KINASE INHIBITORS; RECURRENCE; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 85010049735     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2016.68.2914     Document Type: Article

References (35)

1. Druker BJ, Guilhot F, O'Brien SG, et al: Fiveyear follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355:2408-2417, 2006
2. Gambacorti-Passerini C, Antolini L, Mahon FX, et al: Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib. J Natl Cancer Inst 103:553-561, 2011
3. Kantarjian H, O'Brien S, Jabbour E, et al: Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: A single-institution historical experience. Blood 119:1981-1987, 2012
4. Hochhaus A, O'Brien SG, Guilhot F, et al: Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 23:1054-1061, 2009
5. Larson RA, Hochhaus A, Hughes TP, et al: Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year followup. Leukemia 26:2197-2203, 2012
6. Kantarjian HM, Shah NP, Cortes JE, et al: Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood 119:1123-1129, 2012
7. Cortes JE, Kim DW, Kantarjian HM, et al: Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: Results from the BELA trial. J Clin Oncol 30:3486-3492, 2012
8. Hughes TP, Hochhaus A, Branford S, et al: Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: An analysis from the International Randomized Study of Interferon and STI571 (IRIS). Blood 116:3758-3765, 2010
9. Hehlmann R, Müller MC, Lauseker M, et al: Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: Results from the randomized CML-study IV. J Clin Oncol 32:415-423, 2014
10. Mahon FX, Réa D, Guilhot J, et al: Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: The prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 11:1029-1035, 2010
11. Rousselot P, Huguet F, Rea D, et al: Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood 109:58-60, 2007
12. Ross DM, Branford S, Seymour JF, et al: Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: Results from the TWISTER study. Blood 122:515-522, 2013
13. Thielen N, van der Holt B, Cornelissen JJ, et al: Imatinib discontinuation in chronic phase myeloid leukaemia patients in sustained complete molecular response: A randomised trial of the Dutch-Belgian Cooperative Trial for Haemato-Oncology (HOVON). Eur J Cancer 49:3242-3246, 2013
14. Takahashi N, Kyo T, Maeda Y, et al: Discontinuation of imatinib in Japanese patients with chronic myeloid leukemia. Haematologica 97:903-906, 2012
15. Yhim HY, Lee NR, Song EK, et al: Imatinib mesylate discontinuation in patients with chronic myeloid leukemia who have received front-line imatinib mesylate therapy and achieved complete molecular response. Leuk Res 36:689-693, 2012
16. Mori S, Vagge E, le Coutre P, et al: Age and dPCR can predict relapse in CML patients who discontinued imatinib: The ISAV study. Am J Hematol 90:910-914, 2015
17. Lee SE, Choi SY, Bang JH, et al: Predictive factors for successful imatinib cessation in chronic myeloid leukemia patients treated with imatinib. Am J Hematol 88:449-454, 2013
18. Ross DM, Branford S, Seymour JF, et al: Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR. Leukemia 24:1719-1724, 2010
19. Chomel JC, Bonnet ML, Sorel N, et al: Leukemic stem cell persistence in chronic myeloid leukemia patients with sustained undetectable molecular residual disease. Blood 118:3657-3660, 2011
20. Cross NC, White HE, Müller MC, et al: Standardized definitions of molecular response in chronic myeloid leukemia. Leukemia 26:2172-2175, 2012
21. Legros L, Rousselot P, Giraudier S, et al: Second attempt to discontinue imatinib in CP-CML patients with a second sustained complete molecular response. Blood 120:1959-1960, 2012
22. Rousselot P, Charbonnier A, Cony-Makhoul P, et al: Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease. J Clin Oncol 32:424-430, 2014
23. Rea D, Nicolini FE, Tulliez M, et al: Dasatinib or nilotinib discontinuation in chronic phase (CP)-chronic myeloid leukemia (CML) patients (pts) with durably undetectable BCR-ABL transcripts: Interim analysis of the STOP 2G-TKI study with a minimum follow-up of 12 months: On Behalf of the French CML Group Filmc. Blood 124, 2014 (abstr 811)
24. Richter J, Söderlund S, Lübking A, et al: Musculoskeletal pain in patients with chronic myeloid leukemia after discontinuation of imatinib: A tyrosine kinase inhibitor withdrawal syndrome? J Clin Oncol 32:2821-2823, 2014
25. Lee SE, Choi SY, Song HY, et al: Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: The KID study. Haematologica 101:717-723, 2016
26. Saussele S, Richter J, Guilhot J, et al: First interim analysis of a Pan-European stop trial using standardized molecular criteria: Results of the EUROSKI trial. Haematologica 99, 2014 (abstr 6214)
27. Sanford D, Kyle R, Lazo-Langner A, et al: Patient preferences for stopping tyrosine kinase inhibitors in chronic myeloid leukemia. Curr Oncol 21:e241-e249, 2014
28. Saußele S, Richter J, Hochhaus A, et al: The concept of treatment-free remission in chronic myeloid leukemia. Leukemia 30:1638-1647, 2016
29. Hughes TP, Ross DM: Moving treatment-free remission into mainstream clinical practice in CML. Blood 128:17-23, 2016
30. Mahon FX, Nicolini FE, Noël MP, et al: Preliminary report of the STIM2 study: A multicenter stop imatinib trial for chronic phase chronic myeloid leukemia de novo patients on imatinib. Blood 122, 2013 (abstr 654)
31. Rea D, Rosti G, Cross NC, et al: Enestpath: A phase III study to assess the effect of nilotinib treatment duration on treatment-free remission (TFR) in chronic phase-chronic myeloid leukemia (CP-CML) patients (pts) previously treated with imatinib: Interim analysis from the first year of induction phase. Blood 126, 2015 (abstr 4040)
32. Imagawa J, Tanaka H, Okada M, et al: Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): A multicentre phase 2 trial. Lancet Haematol 2: e528-e535, 2015
33. Hughes TP, Lipton JH, Spector N, et al: Deep molecular responses achieved in patients with CML-CP who are switched to nilotinib after long-term imatinib. Blood 124:729-736, 2014
34. Hochhaus A, Saglio G, Hughes TP, et al: Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia 30:1044-1054, 2016
35. Jabbour E, Kantarjian HM, Saglio G, et al: Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). Blood 123:494-500, 2014